curriculum vitae michael wong jann february 18, 2019 home ... · 2 tcu neeley school of business...
TRANSCRIPT
1
CURRICULUM VITAE
Michael Wong Jann
February 18, 2019
Home Address: NA
Business Address: University of North Texas System College of Pharmacy
University of North Texas Health Sciences Center
Department of Pharmacotherapy
3500 Camp Bowie Blvd
Fort Worth, TX. 76107
(817) 735-2620
Marital Status: Married, Wife: Belinda Lee
Children: Jamieson Trevor
Education: Undergraduate: East Los Angeles Junior College, Los Angeles,
California from 1971-1973. Honor Student. Finance Committee and
Associated Student Body President 1972-1973.
California State University at Los Angeles, Los Angeles, California.
Honor Student, Finance Committee, and graduated with Bachelor of
Science in Biology 1975.
Graduate/Pharmacy: University of Southern California, Los Angeles,
California. Began 1975, received Doctor of Pharmacy June 1979.
Postgraduate: Post-Doctoral Residency in Psychiatric Pharmacy Practice
at the University of Tennessee 1980.
A Short Course in Population Kinetics: NONMEM System. Bethesda,
Maryland, May 1985, License #0255.
Advanced Methods of Pharmacokinetics/Pharmacodynamics. UCSF.
April 10-15, 1988.
Advanced Methods Drug Metabolism and Oxidation. Karolinska
Institute, Stockholm, Sweden. June 25-29, 1990.
American College of Clinical Pharmacy Leadership Training. San
Antonio, TX. Feb. 27 – March 2, 2006.
Visiting Scholar, Taipei City Psychiatric Center, Taipei, Taiwan, Aug.-
Sept. 1991, National Science Council. National Science Council
Scholar, Republic of China, 1992-2004.
2
TCU Neeley School of Business Executive Education – The Adaptive
Leadership Program. September – November 2016.
Professional
Goals: To promote translational research by networking the basic and clinical
sciences with outcomes research for optimizing patient care. To
collaborate with the pharmaceutical industry and the FDA in the drug
and product development. To evaluate the impact and integrate aspects
of urban and rural primary care, precision medicine, public health, and
patient safety. To influence county, state, and federal agencies in the
policies and regulations in health care. To provide the best educational
program to pharmacy and graduate students, post-doctoral graduate
students, residents and fellows. To have a leadership role in the college
of a pharmacy and health sciences center.
Research
Interests: My main research interests include: analysis of the pharmacodynamic
and pharmacokinetics effects of 1. typical and atypical neuroleptics and
antidepressants; 2. pharmacogenomics and age differences in
psychopharmacology and drug metabolism; 3. use of anticonvulsants in
psychiatry and drug interaction between anticonvulsant and psychotropic
drugs; 5. pharmacotherapy of Alzheimer’s Disease and Related
Disorders; 6. Effects of CNS medications use during pregnancy and birth
defects; and 7. Health and Practice Issues with the LGBTQ Population.
Laboratory skills: 1. HPLC worked with fluphenazine and haloperidol
blood levels; 2. Receptor binding with Brandel cell harvester; 3. Guinea
pig and rat surgical procedures; 4. Genotyping PCR and 5. ELISA.
Pharmacy
Licensure: Texas #25574, Georgia #16979. Board Certified Psychiatric Pharmacy
Practice (BCPP), 1999, recertified 2006 #498112. CMS NPI
#1386641421. Certified by APhA in Medication Therapy Management
(MTM) and Immunizations, 2010.
Awards: Chairman’s Essay Award, 1964.
Monterray Optimist Award, 1970.
Sandoz Award, University of Southern California for excellence in
psychopharmacology, 1979.
Certificate of Merit, presented by W. Clements, former Governor of
Texas, 1981.
Roche Hospital Pharmacy Grant, 1983.
Outstanding Young Men of America, 1983.
Organizations: American Society of Health System Pharmacists (ASHP)
American College of Clinical Pharmacology (ACCP), elected Fellow,
1991.
American College of Clinical Pharmacy (ACCP), elected Fellow 1993
American Society of Consultant Pharmacist (ASCP)
Texas Society of Health-Systems Pharmacists (TSHP)
3
Appointments:
A. Academic
1. Professor (with tenure) Department of Pharmacotherapy, University of North Texas System
College of Pharmacy May 2013 to present. Department Chair from May 2013 to December
31, 2017.
2. Professor of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern
School of Pharmacy, July 1993-April 2013. Interim Department Chair Pharmacy Practice
Aug. 2001 – July 2002. Chair, Department of Clinical and Administrative Sciences
(Pharmacy Practice) July 2002 to May 2013. Awarded an endowed Chair in
Neuropsychopharmacology July 2005. Renamed to College of Pharmacy and Health
Sciences 2007.
3. Associate Professor of Pharmacy Practice and Pharmaceutical Sciences, Mercer University
Southern School of Pharmacy. Tenure awarded in 1990. Program Director, Psychiatric
Pharmacy Program, Sept. 1988 to July 1993. Director, Center for Clinical Research Dec.
1990 to Jan. 2006.
4. Clinical Assistant Professor of Pharmacy at the University of Texas at Austin, College of
Pharmacy under Dr. Charles A. Walton and L.C. Littlefield, from September, 1981 to 1988.
Supervision of B.S., Pharm.D. students and residents in the areas of clinical
psychopharmacology. Member of the psychiatry and neurology module lecture series.
Promoted to Clinical Associate Professor 1988.
a. Clinical Assistant Professor 1985-1988
b. Research Scientist 1984-1985
c. Adjunct Assistant Professor 1981-1984
5. Clinical Assistant Professor of Pharmacology, Department of Pharmacology, University of
Texas Health Science Center at San Antonio, 1981 to 1988. Promoted to Clinical Associate
Professor in 1988.
B. Academic Committees and Teaching Assignments. .
1. UNTSCP / UNTHSC:
a. Executive Committee 2013 to 2017.
b. Curriculum Committee 2013 to 2017 (Chair 2013-14).
c. Clinical Preceptor Committee 2013-2017.
d. Student Performance Committee 2016 to present.
e. Faculty Senate Representative Elected by the UNTSCP Faculty 2018 to 2020.
Appointed to the By-Laws Committee.
f. UNTSCP Faculty Representative to the UNTHSC SACS Reaffirmation Committee
2018 to present.
2. COP (Southern School of Pharmacy), Mercer University:
a. Environmental Safety, 1988-89.
b. Graduate Faculty Member; Mercer University, 1989 to present.
c. Academic Performance Committee, 1990-91, 1991-92, 1994-97.
c. Curriculum Committee, 1993-94.
4
d Promotion/Tenure Committee, 1997-99; Chair, 1999-2000.
e. Steering Committee: Physical Facilities and Finance Sections, ACPE reaccreditation
2000-01 and 2007-08.
f. Chemical Dependency, 1999-2006.
g. Member, Institutional Review Board, Mercer University, 1989 - 2000,
Vice-Chair, IRB, 2000-01, Acting-Chair, Summer 2000, Chair, Jan. 2001- Aug. 2001.
h. Executive Committee 2002- present.
3. University of Texas Committees:
a. Member of Preclinical Component Content Development, 1984-85.
b. Chairman, Ad-Hoc Committee on Pharm.D. Award, 1983.
c. Chairman, Subcommittee for Evaluation of R-2 Clerkships, 1986.
d. Joint Pharm.D. Committee, 1981-1988.
4. Course Coordinator Mercer COPHS - Clinical Pharmacokinetics 554, 1995-96; Therapeutics
Nervous System II 451, 2001 to 2003; Therapeutics Nervous System I 450, 2004;
Pharmacotherapy Case Conference PHA 650 2007-2009; Practice of Pharmacy PHA 473 2008;
Introduction to Pharmacy I PHA 306 2007; Introduction to Pharmacy II PHA 307 2007-2008;
Nervous System II PHA 451 2008, 2009. Pharmacy Law PHA 502 2009.
5. Course Director UNTSCP – Self-Care 1 (PHAR 7214) Fall 2013; Self-Care 2 (PHAR 7224)
Spring 2014-2015; Pharmacy Practice 3 (PHAR 7335) Fall 2014; Pharmacy Practice 5 (PHAR
7355) Fall 2015; Hematology-Oncology (PHAR 7361) Spring 2016, 2017; CNS (PHAR 7353)
Fall 2016, 2017; PHAR 7205 LGBT Health and Practice Elective Course.
C. Other Administrative Assignments.
1. Chairman, Institutional Review Board (IRB), San Antonio State School, September 1985
to 1988. Member IRB, September 1984-1985.
2. Administrator on Duty (AOD) San Antonio State School, 1985 to 1988.
3. Administrative Review Team Member for Texas Department of Mental Health and
Mental Retardation (TDMHMR) to review pharmacy services at various state hospitals
(8) and State Schools (13). Inspecting Quality and Standards in Pharmacy Practice,
November 1980 to December 1983.
4. Task Force Member for establishing Guidelines for Administration of Psychoactive
Drugs for TDMHMR and the Department of Justice, September 1981 to December 1981.
5. Chairman of the Task Force to Develop Uniform Standards for Departmental Pharmacies
in TDMHMR from September 1981 to December 1982.
6. Task Force Member to establish the Unit-Dose Drug Distribution System and Hospital
Pharmacy Computer System in Departmental Pharmacies, August 1982 to August 1983.
7. Advisory Committee, Texas State Board of Pharmacy, Preparation of the Texas
Pharmacy Act, Institutional Pharmacy Practice (Class C), 1981.
8. Chief of Pharmacy of Services, San Antonio State Hospital (1100 beds), 1980-1984.
5
9. Clinical Pharmacologist, San Antonio State School, 1984-1988.
10 Educator, Peachford Hospital 2001- present. Supervise pharmacy students and conduct
special research projects.
11. Scientific Advisor, Altea Development Corporation, 2002-06.
C. Organizations
1. Program Director for the Central Texas Society of Hospital Pharmacists January 1982 to
September 1982.
2. Co-Program Director for the Texas Society of Hospital Pharmacist for the TSHP Annual
Seminar for 1984.
3. Member of Contemporary Working Group of the SIG in Psychopharmacy Practice to
develop Standards of Practice, 1983-1984.
4. Subcommittee ASHP SIG Psychopharmacy for the preparation of BPS specialty
recognition, 1986-1992.
5. Nominated for ASHP SIG Psychopharmacy Chairman, 1987.
6. Member of Constitution and By-Laws Committee, ACCP, 1987.
7. Chairperson, Neuropsychopharmacology Symposium, ASCPT Annual Meeting,
Nashville, TN, 1988.
8. Member of Clinical Pharmacy Practice Affairs Committee, ACCP, 1988-89; 1989-90.
9. Chairperson, SPG Psychopharmacy Post-Graduate Training Committee 1989-90, 1990-
91, 1991-92.
10. Chairperson, ACCP Psychiatry Module, Pharmacotherapy Self-Assessment Program,
1990-91.
11. President-Elect, Atlanta Chapter, American College of Clinical Pharmacology, 1992-94.
12. Member of the Research and Education Committee, Atlanta Chapter Alzheimer’s
Association, 1990-92.
13. Member of the Constitution of Bylaws Committee, ASCPT, 1994-96.
14. Psychopharmacy Specialty Council Member, Board of Pharmaceutical Specialties (BPS)
1993-1996.
15. Commission on Therapeutics, ASHP, 1995-96.
16. Nominated, Board of Regents. ACC Pharmacology, 1995, 1996. Elected 2004-2008.
17. Member, Grants and Fellowship Review Committee, ACCP 1999-2001.
6
18. Newsletter editor, ACCPharmacology, 1996-2006
19. Vice-Chair, ACCP Research and Fellowship Awards Committee 2008-09.
20. Member, American College of Clinical Pharmacy Fellowship Credentials Committee
2010-2011.
21. Secretary, Treasurer, and Executive Committee Member, American College of Clinical
Pharmacology 2010-2016.
22. Member, Scientific Board, National Alliance for the Mentally Ill (NAMI), 2010-2014.
23. Community – Tucker First United Methodist Church, Tucker, GA. Staff Parish Relations
Committee 2003-2005; Chair 2005, 2010-2012; Chair 2010. Vice-Chair, Board of
Stewards 2008-09, Co-Chair, Capital Campaign Committee 2008-2010. Member and
Board Member Arlington Heights U.M.C., Fort Worth, TX. 2015 to present.
D. Visiting Scholars of the Psychopharmacy Program.
1. Barbara Baigent, R.Ph., MS, UK, 1994.
2. Fernando Correara, MD, Sweden, 1994.
Graduate Students, Fellows & Residents
Position Taken Upon Program Completion:
A. Janice Shier 1982-1983 Clinical Pharmacist, Children’s Hospital, Detroit, MI.
B. Kathy Kastenholz 1982-1983 Clinical Assistant Professor of Pharmacy, The University of
Texas
C. Dale Grothe 1983-1984 Assistant Professor of Pharmacy, University of Maryland
D. Dance Smith 1983-1984 Clinical Pharmacist, Anoka State Hospital, Adjunct Assistant University of Minnesota
Professor of Pharmacy, University of Minnesota COP
E. Natalie Mendam 1984-1985 Drug Information Center, Ohio State University
F. Judy L. Curtis 1984-1985 Clinical Assistant Professor of Pharmacy, University of
Maryland
G. Cheryl Beal 1985-1986 Assistant Professor of Pharmacy, University of Illinois
H. Cynthia Foslien 1986-1987 Clinical Pharmacist Specialist, V.A. Dallas
I. Mark D. Watanabe 1987-1989 Pharm.D./Ph.D., Assistant Professor, University of Illinois
J. Sara Grimsley 1989-1990 Assistant Professor of Pharmacy Practice, Mercer University
K. Patrick D’Souza 1989-1992 Ph.D., committee, Ph.D. awarded 1992, Post-Doctoral position
at Genetech
7
L. Jolayne Woo 1990-1991 Clinical Pharmacist, Gwinnett Medical Center
M. Eric Gray 1991-1992 Staff Pharmacist, Cobb General Hospital
N. Sharilyn Erickson 1992-1993 VA Clinical Pharmacist, Norfolk, VA
O. Ray Pourfarzib 1991-1993 Ph.D. Committee, Ph.D. awarded 1994, position at Astra-Merck
P. Grace Milton 1993-1994 Ph.D., Post-Doctoral Fellow in Neurosciences, Research
Scientist, Dialysis Clinic, Inc.
Q. Bruce Augustin 1994-1995 Clinical Neuroscience Fellow 1995-1997; Research Scientist,
Solvay Pharmaceuticals 1997.
R. Andy Simpson 1995-1996 Clinical Pharmacist, Western State Hospital, Seattle, WA.
Troy ZumBrunnen 1996-1998 Solvay/Mercer Clinical Research Fellow; Clinical Scientist,
Solvay.
S. Yusuf Kazmi 1996-1999 Research Scientist, Solvay.
Chad VanDenBerg 1996-1999 Associate Director, Clinical Operations, Somerset
Pharmaceuticals
T. Hiral Desai 1999-2001 Medical Science Liaison, Ligand Pharmaceuticals.
U. Kara L. Shirley 2000-2001 Assistant Professor, Pharmacy Practice, Albany College of
Pharmacy, Albany, NY.
Editorial Responsibilities:
A. Editorial Board
1. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd Edition. Eds.
Evans WE, Schertz J, and Jusko W, 1986.
2. Drug Metabolism Drug Interactions, 1991 to 2013.
3. CNS Drugs, ADIS Press, 1993 to present.
4. American College of Clinical Pharmacology, Newsletter, 1995 –2007.
5. Journal of Clinical Pharmacology, 1995 to present. Finalist for Editorship 2004.
6. American Journal of PharmacoGenomics, ADIS Press, 2000 to 2006.
7. Molecular Diagnostics and Therapeutics, ADIS Press, 2006 to present.
8. The Consultant Pharmacist, 2005 to present.
9. The Scientific World Journal – Pharmacology Section, 2011 to present.
10. Journal of Pharmacy Practice, 2015-2019 (4-year term).
8
B. Reviewer
1. Grant applications for Veterans Administration Research and Development, 1987.
2. March of Dimes Foundation, 1990.
3. Site Reviewer NIMH, Dept. of Psychiatry, UCLA, Harbor General Hospital, Torrence,
CA, 1993. Study section in clinical psychopharmacology, NIMH, 1993-94.
4. ACCP Research Institute - Fellowship in Psychopharmacy and CNS Research Award,
1999-2001, 2006.
5. New Zealand, Neurological Foundation, 1998-present.
6. Special panel member for NIA and NIMH grant reviews 2000-04 and 2006.
7. NIH/NCCAM Panel to review RTRC’s 2005, 2006.
C. Journals
1. Reviewer, Pharmacotherapy, 1984, 1985, 1988, 1990, 1993, 1995, 1996-present.
2. American Society of Hospital Pharmacist. Midyear Clinical Meeting Papers. 1982,
1984 and 1985.
3. Clinical Pharmacy, 1985 to 1993.
4. U. S. Pharmacopeia, Neuropsychopharmacology Section, 1986-1991.
5. The Medical Letter, 1986 to present.
6. Hospital Formulary, 1987.
7. Psychopharmacology, 1990, 1996.
8. Psychiatry Research, 1991, 2015.
9. Biological Psychiatry, 1991, 1992, 2007.
10. J Clin Psychopharmacology, 1991, 1992 (3 articles), 1993, 1994, 1995 (4), 1996 (3),
1997 (3), 1998 (2), 1999 (2), 2000 (4), 2001 (3), 2002 (3), 2003 (2), 2004 (3), 2005 (2)
2006 (3), 2007 (2), 2008 (6), 2009 (3), 2010 (2), 2011 (1), 2012 (1), 2013 (1).
11. Clinical Drug Investigations (ADIS Press), 1991, 2011, 2012 (2).
12. Drugs, 1994, 2002.
13. American Journal Health Care Systems Pharmacy, 1995 (2 articles).
9
14. Clinical Pharmacokinetics, 1995, 1997, 1998, 1999 (3 articles), 2000, 2002, 2005, 2009,
2011, 2012.
15. J Clin Pharmacology, 1995 (4 articles).
16. Prog Neuropsychopharmacol Bio/Psychiatry, 1995.
17. Drugs and Aging (ADIS Press), 1995, 2004.
18. Drug Safety (ADIS Press), 1995.
19. Archives of General Psychiatry, 1999, 2007.
20. Journal of Psychiatry and Neuroscience, 2001
21. Neuropsychopharmacology, 2002, 2005 (2 articles), 2006.
22. Naunyn-Schmiedeberg’s Archives of Pharmacology, 2002.
23. Biopharmaceutics and Drug Disposition, 2004.
24. Acta Pharmacologica Sinica, 2005, 2006.
25. Human Psychopharmacology, 2006, 2008, 2009.
26. American Journal of Psychiatry, 2008 (2 articles), 2009, 2010, 2012.
27. Journal of Psychopharmacology, 2008 (4 articles), 2011.
28. Neurotoxicology Research, 2008.
29. Ann Pharmacotherapy, 2009.
30. Clinical Pharmacology and Therapeutics, 2008, 2009, 2010.
31. Journal of Affective Disorders, 2010.
32. Journal of Bioequivalence and Bioavailability, 2012.
33. Journal of Parkinson’s and Restless Leg Syndrome, 2012.
34. British Journal of Clinical Pharmacology, 2012.
35. International Journal of Nanomedicine, 2012.
36. PLoS One, 2013, 2014.
37. Clinical Therapeutics, 2014.
38. Acta Neuropsychiatrica, 2015.
39. American Journal of Public Health, 2015.
10
40. British Medical Journal, 2018.
Publications: As of March 2018 h-index: 40; i10-index 92; and Citations 5,708
Publications (Journal Issue): 135
1. Editor: Neurology and Psychiatry Module. PSAP Pharmacotherapy, ACCP, 1992, 1st edition, 1995,
2nd edition.
2. Co-Editor: Pharmacogenetics. Journal of Pharmacy Practice, December 1992, February 1993.
3. New Product Bulletin - American Pharmaceutical Association.
a. Paroxetine (Paxil) - Editor
b. Venlafaxine (Effexor) - Board Member
c. Special Issues - Depression - Board Member
4. Fluvoxamine Supplement Issue (7 articles) - Clinical Pharmacokinetics, 1995.
Textbook:
Jann MW, Penzak SR, Cohen LJ, eds. Applied Clinical Pharmacokinetics and Pharmacodynamics of
Psychopharmacological Agents, 1st Edition, Springer Press, Spring 2016. Launched April 10, 2016.
As of April 20, 2018 – 20,180 chapter downloads (Bookmetrix).
Chapters:
1. Ereshefsky L, Jann MW: Lithium. In: Applied Clinical Pharmacokinetics. Ed. Mungall D.,
Raven Press Inc. 1983, 245-270.
2. Ereshefsky L, Respond R, Jann MW: Organic Brain Syndromes. In: Clinical Therapeutics. Ed.
Posey M., Elsevier Press. 1988, p. 678-696.
3. Crismon ML, Jann MW: Anxiety and Insomnia. In: Applied Therapeutics. 4th Edition, Eds.
Koda-Kimble M, Young L and Applied Therapeutics Inc. 1988, p. 1155-1188.
4. Jann MW: Anxiety Disorders. In: Applied Therapeutics. 5th Edition. Eds. Koda-Kimble M and
Young L. 1992, p. 54-1 to 54-21.
5. Jann MW, Lam YWF, Chang WH: Haloperidol and Reduced Haloperidol Plasma Concentrations
in Different Ethnic Populations and Interindividual Variabilities in Haloperidol Metabolism. In:
Psychopharmacology and Psychobiology of Ethnicity. Eds. Lin KM, et at, Amer. Psychiatric
Association Press, Inc. 1993, p. 133-152.
6. Jann MW and VanDenBerg CM: Dementia. PSAP. 3rd edition, 1998, p. 67-90.
7. Jann MW, Awad EA. Clinical trials with rivastigmine in mild to moderate dementia. In:
Research and Practice in Alzheimer's Disease vol. 5. Acetylcholinesterase inhibitors. Eds. Vellas
B, et al., 1999, p. 67-75.
8. Shirley KL and Jann MW. Dementia. PSAP. 4th edition, 2002, p. 167-201.
11
9. Jann MW and Small GW. Cholinesterase Inhibitors and Similarly Acting Compounds. In.
Comprehensive Textbook of Psychiatry. Eds. Sadock BJ and Sadock VA., 8th Ed., Williams and
Wilkins, MD. 2005, Chapter 31.15, p. 2808-2817.
10. Perel J, Jann MW. Antipsychotics. In: Pharmacokinetics and Pharmacodynamics: Principles of
Therapeutic Drug Monitoring. 4th ed. Eds. Evans WE, et al., 2006, Chapter 32, p. 813-838.
11. Jann MW, Brennan J, VanDerHoop R. Psychiatry. Drug Development. Ed. Evans R.. Springer,
2007, p. 338-350.
12. Jann MW and Small GW. Cholinesterase Inhibitors and Similarly Acting Compounds. In.
Comprehensive Textbook of Psychiatry. Eds. Sadock BJ and Sadock VA., 9th Ed., Williams and
Wilkins, MD. ,Chapter 31.15, 2009, p. 3089-3099.
13. Jann MW, Kennedy WK. Safety and Tolerability of Antipsychotics. In: Pharmacovigilance in
Psychiatry. Eds. Spina, E., and Trifiro, G. Springer ADIS, 2016, Chapter 9, p. 167-190.
14. Jann MW, Kennedy WK. Antipsychotics. In: Applied Clinical Pharmacokinetics and
Pharmacodynamics of Psychopharmacological Agents. Jann MW, Penzak SR, Cohen LJ, eds 1st
Edition, Springer Press, Spring 2016, p. 139-176.
15. VanDenBerg CM, Jann MW. Antidementia Drugs. In: Applied Clinical Pharmacokinetics and
Pharmacodynamics of Psychopharmacological Agents. Jann MW, Penzak SR, Cohen LJ, eds 1st
Edition, Springer Press, Spring 2016, p. 329-350.
16. Jann MW. Antiaddiction Drugs. In: Applied Clinical Pharmacokinetics and Pharmacodynamics
of Psychopharmacological Agents. Jann MW, Penzak SR, Cohen LJ, eds 1st Edition, Springer
Press, Spring 2016, p. 351-372.
17. Jann MW. Anesthetics. In: Applied Clinical Pharmacokinetics and Pharmacodynamics of
Psychopharmacological Agents. Jann MW, Penzak SR, Cohen LJ, eds 1st Edition, Springer Press,
Spring 2016, p. 373-394.
18. Jann MW. Drug Interactions with Anesthetic Drugs. In: Applied Clinical Pharmacokinetics and
Pharmacodynamics of Psychopharmacological Agents. Jann MW, Penzak SR, Cohen LJ, eds 1st
Edition, Springer Press, Spring 2016, p. 579-601.
Articles:
1. Hodding G, Jann MW, Ackerman I: Drug Withdrawal Syndromes: A Literature Review.
Western Journal of Medicine. Nov. 1980; 133-383-391.
2. Jann MW, Bitar AH: Respiratory Dyskinesia. Medicine and Psychiatry. May 1982; 139:684-
686.
3. Jann MW, Bitar AH, Rao A: Lithium Prophylaxis of Tricyclic Antidepressant-induced Mania in
Bipolar Patients. American Journal of Psychiatry. May 1982; 139:684-686.
4. Ereshefsky L, Davis DM, Harrington CA, Jann MW, Browning JL, Saklad SR, Burch N:
Haloperidol and Reduced Haloperidol Plasma Levels in Selected Schizophrenic Patients.
Journal of Clinical Psychopharmacology 1984; 4(3):138-142.
12
5. Jann MW, Garretts JC, Ereshefsky L, Saklad SR: Alternative Drug Therapies for Mania: A
Literature Review. Drug Intelligence Clinical Pharmacy 1984; 18:577-589.
6. Saklad SR, Ereshefsky L, Jann MW, Crimson ML: Changes in Psychotherapeutic Prescribing
Patterns After Implementing Clinical Pharmacy Services. Drug Intelligence Clinical Pharmacy
1984; 18:632-635.
7. Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A: Future of Depots Antipsychotics:
Pharmacokinetics and Pharmacodynamic Approaches. Journal of Clinical Psychiatry 1984;
45:50-59 (supplement).
8. Jann MW, Richards A: Selection of Antipsychotic Drugs in Medical and Psychiatric Emergency
Situations. U.S. Pharmacist 1985; 10:H1-H13 (requested article).
9. Jann MW, Ereshefsky L, Saklad SR: Clinical Pharmacokinetics of the Depot Antipsychotics.
Clinical Pharmacokinetics 1985; 10:315-333.
10. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch N, Bowden CL: Effect of
Carbamazepine on Plasma Haloperidol Levels. Journal of Clinical Psychopharmacology 1985;
5:106-109.
11. Ereshefsky L, Jann MW, Saklad SR, Richards A, Davis CM, Burch N: Effect of Smoking on
Plasma Fluphenazine Levels in Psychiatric Inpatients. Biological Psychiatry 1985; 5:106-109.**
12. Birkhimer L, Curtis JL, Jann MW: Carbamazepine’s Use in Psychiatric Disorders. Clinical
Pharmacy 1985; 4:425:434.**
13. Jann MW, Fidone G: Effects of Influenza Immunization of Anticonvulsant Plasma Levels.
Clinical Pharmacy 1986; 5:817-820.
14. Jann MW, Saklad SR, Ereshefsky L, Harrington CA, Davis CM, Richards AL: Effects of
Smoking on Haloperidol and Reduced Haloperidol Plasma Concentrations and Haloperidol
Clearance. Psychopharmacology 1986; 90:468-470.
15. Ereshefsky L, Jann MW, Saklad SR, Davis CM: Bioavailability of Psychotropic Drugs:
Historical Perspective and Pharmacokinetic Overview. J Clin Psychiatry 1986: 47(9) Suppl:6-
15.
16. Jann MW, Fidone G, Gorday M, Rosedt RR: Use of Butorphanol of Dental Sedation in Mentally
Retarded. J Oral Dent Oral Path Oral Surg 1987; 63:403-408.
17. Jann MW, Kurtz NM: Treatment of Phobic and Panic Disorders. Clin Pharmacy 1987; 6:947-
962.
18. Jann MW: Buspirone: An Update on a Unique Anxiolytic Agent. Pharmacotherapy 1988; 8:100-
116.
19. Jann MW, Fidone GS: Increase in Serum Valproic Acid Concentrations Upon Carbamazepine
Cessation. Epilepsia 1988; 29:578-581.
13
20. Jann MW, Fidone GS, Davis CM, Hernandez JM: Clinical Implications of Increased Serum
Neuroleptic Concentrations Upon Carbamazepine Cessation. Psychiatry Research 1989; 28:153-
159.
21. Chang WH, Lin SK, Jann MW, Lam YW, Chen TY, Chen CT, Hu WH, Yeh EK:
Pharmacodynamic and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic
patients. Biol Psychiatry, 1989; 26:239-249.
22. Froemming J, Lam YWF, Jann MW, Davis CM. Clinical Pharmacokinetics of haloperidol.
Clinical Pharmacokinetics 1989; 17: 394-421.**
23. Jann MW, Chang WH, Davis CM, et at: Plasma Haloperidol and Reduced Haloperidol
Concentrations in Chinese and Non-Chinese Schizophrenics. Psychiatry Research 1989; 30:45-
52.
24. Lin SK, Jann MW, Chang WH: Pharmacokinetics of haloperidol in Chinese Schizophrenic
patients. Chinese Psychiatry 1989; 3:80-88.
25. Chang WH, Lin SK, Jann MW, Yeh EK: Pharmacokinetics and Pharmacodynamics of Reduced
Haloperidol: Comparison with Haloperidol, Chin Psychiatry 1989; 3:45-59.
26. Jann MW, Lam YWF, Chang WH. Reversible Metabolism Haloperidol and Reduced Haloperidol
in Chinese Schizophrenic Patients. Psychopharmacology 1990; 101:107-111.
27. Jann MW, Froemming JH, Borison RL: Movement Disorders and New Azapirone Anxiolytic
Drugs. Journal of the American Board of Family Practice 1990; 3(2):111-119.
28. Jann MW, Grimsley SR: Drugs of Abuse. Pharmat 1990; 16(4):1-18.
29. Chang WH, Lin SK, Jann MW: Interconversion between Haloperidol and Reduced Haloperidol
in Schizophrenic Patients and Guinea Pigs. J Clin Psychopharmacol 1991; 11:99-105.
30. Grimsley SR, Jann MW, D’Mello A, D’Souza MJ, Carter GC: Increased carbamazepine plasma
concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15.**
31. Jann MW: Clozapine. Pharmacotherapy 1991;11:179-195.
32. Chang WH, Jann MW, Hwu HG, Chen TY, et al: Ethnic comparison of haloperidol and reduced
haloperidol plasma levels: Chinese vs. Non-Chinese. J Fozmosam Med Assoc 1991;90:572-578.
33. Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW: Thiothixene pharmacokinetics
interactions. J Clin Psychopharmacol 1991;11:296-301.
34. Jann MW, Chang WH, Lam YWF, et al: Comparative analysis of haloperidol and reduced
haloperidol in different ethnic populations. Prog Neuropsychopharmacol Biol Psychiatry 1992;
16:193-202.
35. Miller SW, Mahoney J, Jann MW: Frontiers in the treatment of Alzheimer’s Disease.
Pharmacotherapy 1992; 12:217-231.
14
36. Chang WH, Lam YWF, Jann MW, Chen H: Pharmacokinetics of haloperidol and reduced
haloperidol in Chinese schizophrenics after intravenous and oral administration.
Psychopharmacology 1992; 106:517-522.
37. Lam YWF, Chang WH, Jann MW, Chen H: Variabilities in haloperidol interconversion and the
reduced haloperidol/haloperidol ratio. Neuropsychopharmacology 1992; 7:103-109.
38. Grimsley SR, Jann MW: Fluvoxamine, sertraline and paroxetine. Serotonergic Reuptake
Inhibitors: Clinical Implications for Serotonin in Neuropsychiatry. Clin Pharm 1992; 11:930-
957.
39. Chang WH, Lin SK, Lam YWF, Jann MW: Prolonged haloperidol and reduced haloperidol
plasma concentrations after decanoate withdrawal. Schizophrenia Research 1993; 9:35-40.
40. Chang WH, Lin SK, Lam YWF, Jann MW: Reduced haloperidol/haloperidol ratios after
haloperidol oral and decanoate administration. Prog Neuropsychopharmacol Biol Psychiatry
1993; 17:105-112.
41. Chang WH, Lin SK, Juang DJ, Chen LC, Yang CH, Lane HY, Jann MW. Effects of haloperidol
decanoate on plasma homovanillic acid in chronic schizophrenis patients. Biol Psychiatry 1993;
33: 557-559.
41. Lin SK, Chang WH, Lam YWF, Jann MW: Variability in declining haloperidol and reduced
haloperidol plasma concentrations upon haloperidol cessation. Drug Investigations 1993;5:57-
62.
42. Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacokinetic and pharmacodynamics of
Clozapine. Clin Pharmacokinetics 1993; 24:161-176.
43. Jann MW, Grimsley SR: Pharmacogenetics of Agents Acting on the Central Nervous System. In:
Jann MW and Lam YWF (eds.) Pharmacogenetics. Journal of Pharmacy Practice, 1993; 6:2-16.
44. Jann MW, Lam YWF: Future Directions. In: Jann MW and Lam YWF (eds), Pharmacogenetics.
Journal of Pharmacy Practice 1993; 6:44-46.
45. Chung MC, Jann MW, Chang WH: Determination of clozapine and N-desmethylclozapine in
human plasma by high performance liquid chromatography with ultraviolent detection. J
Chromatography Biomed Application 1993; 613:168-173.
46. Chang WH, Lin SK, Juang DJ, Chen LC, Yang CH, Jann MW, Hu WH, Chien CP: Effects of
Haloperidol Decanoate on and Seasonal Variation of Plasma Homovanillic Acid in Chronic
Schizophrenic Patients. Biol Psychiatry 1993; 33:557-559.
47. Lin SK, Chang WH, Lam YWF, Jann MW: Pharmacodynamics and pharmacokinetics of
Clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 1994; 34:318-
324.
48. Jann MW, Gray EC, Lam YWF, Chang WH: Reversible metabolism of drugs. Drug Metabolism
Drug Interaction 1994; 11:1-25.
15
49. Chang WH, Shieh YS, Lin HC, Jann MW, Chien CP: Plasma Reduced Haloperidol to
Haloperidol Ratios in Schizophrenic Patients Treated with High Doses of Haloperidol. European
Journal of Neuropsychopharmacology 1994; 4:119-126.
50. Jann MW, Huang HF, Lin SK, et al: Pharmacodynamics and Pharmacokinetics of Haloperidol
and Reduced Haloperidol After Intramuscular Haloperidol Administration in Schizophrenic
Patients. Drug Investigations 1994; 7:18-25.
51. Jann MW, Chang WH,: Reversible metabolism of clozapine and clozapine-n-oxide. Arch Int.
Pharmacodynamic 1994; 328:243-250.
52. Pritchard WS, Duke DW, Colburn KL, Moore NC, Tucker KA, Jann MW, Hostetler R: EEG-
based, neural-net, predictive classification of Alzheimer’s Disease versus control subjects is
augmented by non-linear EEG measures. Electroencephalography and Clinical Neurophysiology
1994; 91:118-130.
53. Lam YWF, Jann MW, Chang WH, et al: Polymorphism in Reduced Haloperidol to Haloperidol
Ratios in Different Ethnic Groups. J Clin Pharmacol 1995; 35:128-136.
54. Chang WH, Juang DJ, Lin SK, Lan YWF, Jann MW, Chien CP: Disposition of haloperidol and
reduced haloperidol plasma levels after single dose haloperidol decanoate administration. Human
Psychopharmacology 1995; 10:47-51.
55. Huang HF, Jann MW, Tseng YT, Chung MC, Chien CP, Chang WH: Ketone reductase activity
and reduced haloperidol/haloperidol ratios in haloperidol treated patients. Psychiatry Research
1995; 57:101-108.
56. Moore NC, Tucker KA, Jann MW, Hostetler RM, Colburn KL: Flash P2 delay in PDD of the
Alzheimer’s Type. Prog Neuropsychopharmacol Biol Psychiat 1995; 19:403-410.
57. Milton G, Jann MW. Emergency treatment of psychotic symptoms. Clinical Pharmacokinetics
1995; 28:494-504.
58. Lane HY, Lin HN, Hwu HG, Jann MW, Hu WH, Chang WH: Haloperidol plasma
concentrations in Taiwanese psychiatric patients. J Formos. Med Assoc. 1995; 94:671-678.
59. Lin SK, Wei FL, Lin HC, Chung MC, Chang WH, Jann MW. Monitoring plasma levels of
clozapine and its metabolites in refractory schizophrenic patients. Ther Drug Monitoring 1996;
18:200-207.
60. Lin SK, Chang WH, Jann MW. Clinical Pharmacokinetics of remoxipride in Chinese
schizophrenia patients. Intl J Clin Pharmacol Ther 1996; 34:17-20.
61. Chang WH, Jann MW, Chiang TS, Lin HN, Hu WH, Chien CP: Monitoring plasma haloperidol
and reduced haloperidol concentrations in a geriatric hospital. Neuropsychobiology 1996; 33:12-
16.
62. Morich FJ, Bieber F, Lewis JM, and the North American Nimodipine Study Group:
Nimodipine in the Treatment of Probable Alzheimer’s Disease. Clinical Drug Inv 1996;
11:185-195.
16
63. Jann MW, Wei FC, Lin HN, Chien CP, Chang WH: Reduced haloperidol/haloperidol ratios
during a haloperidol loading dose regimen. Prog Neuropsychopharmacol Biol Psychiatry 1996;
20:73-86.
64. Wei FC, Jann MW, Lin HN, Chien CP, Chang WH: A practical loading dose method for
converting schizophrenic patients from oral to depot haloperidol therapy. Journal of Clinical
Psychiatry 1996; 57: 298-302.
65. Huang HF, Jann MW, Chang WH, et al: Lack of pharmacokinetic interaction between buspirone
and haloperidol in schizophrenic patients. J Clin Pharmacol 1996; 36: 963-969.
66. Lane HY, Lin HN, Hu OYP, Chen CC, Jann MW, Chang WH: Blood levels of reduced
haloperidol vs. clinical efficacy and extrapyramidal side effects of haloperidol. Prog.
Neuropsychopharmacol Biol Psychiatry 1997; 21:299-311.
67. Jann MW, Crabtree BL, Potts WM, Carter JG: Plasma alpha-one acid glycoprotein and
haloperidol concentrations in schizophrenic patients. Neuropsychobiology 1997; 36:32-36.
68. Augustin BG, Cold JA, Jann MW: Venlafaxine and nefazodone: two new antidepressants
unrelated to serotonergic uptake inhibitors. Pharmacotherapy 1997; 17:511-530.
69. Lane HY, Hu, OYP, Jann MW, Deng HC, Lin HC, Chang WH: Dextromethorphan phenotyping
and haloperidol disposition. Psychiatry Res., 1997; 69:105-111.
70. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN: Clozapine dosages and plasma drug
concentrations. J Formos Med Assoc., 1997; 96(No 8):599-605.
71. Jann MW, Liu HC, Lin SK, Wei FE, Hu WH, Chang WH: Gender differences in plasma
clozapine concentrations and its metabolites in schizophrenic patients. Human
Psychopharmacology, 1997; 12:489-495.
72. Lane HY, Chang WH, Chang YC, Hu OYP, Lin HN, Jann MW, Hu WH. Dose-dependent
reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry
Research, 1997; 72:127-132.
73. Chang WH, Hwang RR, Juang DJ, Wu ST, Chang SC, Hu WH, Lam YWF, Jann MW:
Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog.
Neuropsychopharmacol Biol Psychiatry, 1998; 22:723-739.
74. Jann MW, Cohen LJ: Formulary management of oral antipsychotics. Dis Management of Health
Outcomes, 1998; 3:115-129.
75. ZumBrunnen T, Jann MW: Antipsychotic drug interactions. CNS Drugs, 1998; 9:381-401.
76. Cold JA, ZumBrunnen TL, Simpson MA, Augustin BG, Awad E, Jann MW: Increased lithium
serum and red blood cell concentrations during Ketoralac coadministration. J Clin
Psychopharmacol, 1998: 18:33-37.
77. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward EA, Adams L, Fox JL, Weidler D:
Bioavailability of ondansetron 8 mg tablets versus two extemporaneous suppository 16 mg
gender differences. Pharmacotherapy, 1998; 18:288-294.
17
78. Jann MW. Preclinical pharmacology of acetylcholinesterase inhibitors. Pharmacotherapy, 1998;
18:55S-67S.
79. Jann MW. Second generation acetylcholinesterase inhibitors. Am J Health Syst Pharm, 1998;
55(2):522-525.
80. Chiu CC, Jann MW, Lane HY, Liu HC, Chen CH, Chang WH. Disposition of clozapine ,
desmethylclozapine and clozapine n-oxide in Chinese schizophrenic patients. Taiwanese J
Psychiatry, 1998; 12:27-35.
81. Crismon ML, Stimmel GL, Wells BG, Love R, Faukhauser M, Jann MW, et al. Psychiatric
pharmacy practice speciality certification process. Role delineation and examination
preparation. Am J Health System Pharmacists, 1998; 55:1594-1598.
82. Corey-Bloom J, Anand R, Veach J, and the ENA 713 B352 Study Group. A randomized trial
evaluating the efficacy and safety of ENA 713 (rivastigmine), a new acetylcholinesterase
inhibitor, on patients with mild to moderate Alzheimer’s Disease. Int J Geriat Psychopharmacol,
1998; 1:55-65.
83. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka B, Gulanski B. Effects of metrifonate
on the cognitive, global, and behavioral function of Alzheimer’s disease patients: results of a
randomized, double-blind, placebo-controlled study. Neurology, 1998; 50:1222-1229.
84. Cummings J, Cyrus P, Bieber F, et al. Metrifonate treatment of the cognitive deficits of
Alzheimer’s disease. Neurology, 1998; 50:1214-1221.
85. Jann MW, Cyrus P, Bieber F, Gulanski B and the Metrifonate Study Group. The impact of a
loading dose regimen versus non-loading dose regimen on the safety and efficacy of metrifonate
in the symptomatic treatment of Alzheimer’s disease. Clin Therapeutics, 1999; 21:88-102.
86. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on
plasma levels of clozapine and its metabolites. J Clin Psychiatry, 1999; 60:36-40.
87. Raskind M, Cyrus PA, Ruzicka BB, Gulanski MD and the Metrifonate Study Group. The effects
of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer’s disease
patients. J Clin Psychiatry, 1999; 60:318-325.
88. Steele C, Steinberg M, Milles G, Milles G, Jann MW. Management and treatment of early
Alzheimer’s
disease. J Clin Outcomes Mgt, 1999; 6:52-68.
89. Chang WH, Lane HY, ZumBrunnen T, Augustin B, Kazmi YR, Jann MW. In-vitro and in-vivo
evaluation of the drug-drug interaction between fluvoxamine and clozapine.
Psychopharmacology, 1999; 145:91-98.
90. Jann MW. Rivastigmine: a new generation cholinesterase inhibitor for the treatment of
Alzheimer’s Disease. Pharmacotherapy, 2000; 20: 1-12.
91. VanDenBerg CM, Kazmi Y, Jann MW. Safety and tolerability of cholinesterase inhbitors in
Alzheimer’s Disease patients. Drugs and Aging, 2000; 16: 123-138.
18
92. Lane HY, VanDenBerg CM, Liu SK, Jann MW, Chang WH. Disposition of olanzapine in
Chinese schizophrenics. Int J Clin Pharmacol Ther, 2000; 38: 482-485.
93. VanDenBerg CM, Kazmi Y, Stewart J, Tenjarla S, Weidler DJ, Jann MW. Pharmacokinetics of
ondansetron administered intravenously, oral tablet and extemporaneous suppository in healthy
volunteers. Am J Health System Pharm, 2000: 57: 1046-1050.
94. Jann MW, Cohen LT. The influence of ethnicity and antidepressant pharmacogenetics in the
treatment of depression. Drug Metabolism and Drug Interactions, 2000; 16: 39-67.
95. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine to reduce the need
for clozapine in refractory schizophrenic patients. J Clin Psychiatry, 2000; 61: 594-599.
96. Desai HD, Jann MW. Depression and Women’s Health. Journal of the American
Pharmaceutical Association, 2000; 40: 525-537
97. Falek A, Jann MW. Pharmacogenetics and pharmacogenomics: public policy and bioethical
issues associated with patents for drug development. Global Bioethics, 2000; 12: 27-39.
98. Aitchison KJ, Jann MW, Zhao J, Sakai T, Zaher H, Wolff K, Makoff AJ, Collier DA, Kerwin
RW, Gonzalez FJ. Clozapine pharmacokinetics studied with CYP 1A2 knockout mice. J
Psychopharmacol, 2000; 14: 353-359.
99. Jann MW, Grossberg G. Cholinesterase inhibitors in the treatment of Alzheimer's Disease.
Consultant Pharmacist 2000; 15(suppl. B): 7-15.
100. Desai HD, Seabolt J, Jann MW. Effects of smoking upon psychotropic drugs: a
pharmacokinetic perspective. CNS Drugs 2001; 15: 471-496.
101. Jann MW, Shirley KL, Falek A. The impact of cloning in pharmaceutical development
and human therapeutics. Global Bioethics, 2001; 14: 47-51.
102. Penzak SR, Jann MW, Cold JA, Hon YY, Desai H, Gurley BJ. Seville orange juice:
synephrine content and effect on blood pressure in healthy subjects. J Clin Pharmacol, 2001; 41:
1059-1063.
103. Lane HY, Lin SK, Kazmi Y, Desai HD, Jann MW, Chang WH. Lack of interaction
between grapefruit juice and ketoconazole with single clozapine dose in schizophrenic patients.
Drug Metabolism and Drug Interactions, 2001: 18: 263-278.
104. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics of cholinesterase
inhibitors in the treatment of Alzheimer’s Disease. Clin Pharmacokinet, 2002; 41(10): 719-739.
105. Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desia HD, Jann MW. Effect
of Seville orange juice on indinavir pharmacokinetics in healthy volunteers. J Clin Pharmacol
2002; 42: 1165-1170.
106. Jann MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ,
Flockhart DA. Pharmacokinetics of fluvoxamine in relation to CYP 2C19 phenotype and
genotype. Drug Metabolism and Drug Interactions, 2002; 19: 1-11.
19
107. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of
ritonavir on olanzapine pharmacokinetics. J Clin Psychopharmacol 2002; 22: 366-370.
108. Jann MW, Bunt RM. Switching antipsychotic drugs: a pharmacokinetic,
pharmacodynamic and practical perspective. Psychopharmcol Bull 2002; 36: 22-41.
109. Shirley KL, Hon YY, Penzak SR, Lam YWF, Spratlin V, Jann MW. Correlation of
cytochrome P4501A2 activity with olanzapine disposition in healthy volunteers.
Neuropsychopharmacology, 2003; 28: 961-966.
110. Desai H, Shirley KL, Penzak SR, Strom JG, Hon YY, Spratlin V, Jann MW.
Pharmacokinetics of sumatritpan 25 mg oral tablet versus 25 mg extemporaneous suppository in
healthy volunteers. Int J Pharmaceutical Compounding 2003; 7: 481-484.
111. Chui CC, Lane HY, Huang MC, Liu HC, Jann MW, Hon YY, Chang WH, Lu ML.
Dose-dependent fluvoxamine-olanzapine drug interaction study in patients with schizophrenia. J
Clin Pharmacology 2004; 44: 1385-1390.
112. Zheng J, Jann MW, Hon YY, Shamsi SA. Development of capillary zone
electrophoresis-electrospray ionization mass spectrometry for the determination of lamotrigine in
human plasma. Electrophoresis 2004; 25: 2033-2043.
113. Jann MW. New implications for atypical antipsychotics in the treatment of
schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy, 2004;
24: 1759-1783.
114. Hon YY, Jusko WJ, Spratlin VE, Jann MW. Altered methylprednisolone
pharmacodynamics in healthy subjects with histamine N-methyltrasnferase C314T genetic
polymorphism. J Clin Pharmacol 2006; 46: 408-419.
115. Jann MW, Hon YY, Shamsi SR, Zheng J, Awad EA, Spratlin V. Lack of a
pharmacokinetic interaction between lamotrigine and olanzapine. Pharmacotherapy, 2006: 26:
627-633. .
116. Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G, Spratlin VE, Jann MW. Pilot
investigation of endogenous histamine and cortisol concentrations in subjects with different
histamine N-methyltransferase C314T genotypes .Molecular Diagnostics and Therapy (formerly
Am J Pharmacogenomics), 2006; 10: 109-114..
117. Matesic DF, Abifadel DN, Garcia EL, Jann MW. Effect of thioridazine on the major
cardiac gap junction subtype. Cell Biology and Toxicology, 2006; 24:1-12. .
118. Lee SJ, Salaita CG, Jusko WJ, Jann MW, Spratlin VE, Goldstein JA, Hon YY. Reduced
methylprednisoline clearance causing prolonged pharmacodynamics in a healthy subject was not
associated with CYP3A5*3 allele or a change in diet consumption. J Clin Pharmacol 2006; 46:
515-526.
119. Jann MW, Slade HY. The biologic link and antidepressant pharmacotherapy for chronic
pain and depression. Pharmacotherapy, 2007; 27: 1571-1587.
120. Tsai GE, Lane HY, VanDenBerg CM, Liu YC, Tsai P, Jann MW. Disposition of D-
serine in healthy adults.J Clin Pharmacol, 2008; 48: 524-527.
20
121. Jann MW. How effective is pharmacologic therapy in Alzheimer’s Disease: are we
making progress? Consult Pharm 2009; 23: 209-216. .
122. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso
T, Honein MA and the National Birth Defects Prevention Study. Maternal treatment with opioid
analgesics and risk for birth defects. Am J Obstet Gynecol, 2011; 204: 1.e.1 – 1.e.11.
123. Jann MW. Advanced strategies for treatment of Parkinson’s Disease: the role of early
treatment. Am J Managed Care 2011; 17: 1 (suppl.): S315-S321.
124. Jann MW, Spratlin V, Momary KM, Zhang H, Turner D, Penzak SR, Wright A,
VanDenBerg CM. Lack of pharmacokinetic drug-drug interaction study with venlafaxine
XR/indinavir and desvenlafaxine /indinavir in healthy volunteers. Eur J Clin Pharmacol, 2011
DOI 10.1007/s—228-011-1180-7 on line published Dec. 16, 2011. Print citation 2012; 68: 715-
721.
125. Wang X Hou J, Jann MW, Hon C, Shamsi S. Development of chiral micellular
electrokinetic chromatography tandem mass spectrometry assay for simultaneous analysis of
warfarin and hydroxywarfarin metabolites: Application to the analysis of patient serum samples.
J Chromatog Applic 2013; 1271 (1): 207-216.
126. Kennedy WK, Jann MW, Kutcher E. Clinically significant drug interactions with
atypical antipsychotics. CNS Drugs 2013; 27 (12): 1021-1048 doi:10.1007/s40263-013-0114-6.
127. Jann MW, Kennedy WK, Lopez G. Benzodiazepines: an overlooked class of prescription
drugs in unintentional overdoses. Journal of Pharmacy Practice 2014; 27 (1): 5-16 doi:
10.1177/089719001355001.
128. Metzger N, Paciullo CA, Jann MW, Glascock J, Emamifar A, Matthews HW. A unique
collaboration between a private college of pharmacy and a private academic health system.
Hospital Pharmacy, 2014; 49: 634-638.
129. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a managed care
perspective. Amer Health Drug Benefits, 2014; 7: 489-499.
130. Liu Y, Jann MW, Vandenberg CM, Eap CB, Shamsi SA. Development of an
enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine
by micellar electrokinetic chromatography-tandem mass spectrometry: application to the analysis
of drug-drug interaction. J Chromatogr A 2015, dx.doi.org/10.1016/j.chroma.2015.09.088.
131. Jann MW and Penzak SR. Newer long-acting injectable formulations of atypical
antipsychotics. CNS Drugs 2018; 32: 241-257, doi:org./10.1007/s40263-018-0508-6
132. Interrante JD, Scroggs SLP, Hogue CJ, Friedman M, Reefhuis J, Jann MW, Broussard
CS. Opioid use during pregnancy and risk for preterm birth and low birth weight. Under review
Pharmacoepidemiology and Drug Safety.
133. Jann MW, Penzak SR, White A, Tatachar A. An elective course in lesbian, gay, bisexual,
and transgender (LGBT) health and practice issues. Accepted Jan. 18, 2019 to AJPE.
21
134. Redfern J, Jann MW. The evolving role for pharmacists in transgender healthcare.
Revised paper submitted to LGBT Health.
135. Yuet WC, Derasari D, Sivoravong J, Mason, D, Jann MW. Selective serotonin reuptake
inhibitor antidepressants and bleeding. J. Amer. Osteopathic Assoc. 2019; 119: 102-111.
** Denotes corresponding author.
Abstracts:
1. Jann MW, LaMotte J, Rao A, et al: Prophylactic Effects of Lithium on the Switch Process in
Bipolar Depressed Patients Treated with Tricyclic Antidepressants, 15th Annual Midyear
Clinical Meeting by the American Society of Hospital Pharmacists. December, 1980.
2. Wells B, Jann MW: Lithium Neurotoxicity at Therapeutic Serum Levels, Abstract 15th Annual
Midyear Clinical Meeting by the American Society of Hospital Pharmacy. December, 1980.
3. Ereshefsky L, Jann MW, Saklad SR, and Davis CM: Hydroxyhaloperidol Plasma Levels in
Schizophrenic Patients. Drug Intelligence and Clinical Pharmacy 1982; 16:472-473.
4. Jann MW, Saklad SR, and Ereshefsky L: Carbamazepine Treatment of Psychiatric Inpatients
with Affective Symptoms, 17th Annual American Society of Hospital Pharmacists Midyear
Clinical Meeting. December, 1982.
5. Ereshefsky L, Saklad SR, Jann MW, Richards A, and Davis CM: Pharmacokinetics of
Fluphenazine (FPZ) by High Performance Thin Layer Chromatography. Drug Intelligence
Clinical Pharmacy 1983; 17:436-437.
6. Ereshefsky L, Saklad SR, Jann MW, Richards A, and Davis CM: Pharmacokinetics of
Fluphenazine (FPZ) by High Performance Thin Layer Chromatography. Proc Am Coll
Neuropsychopharmacol Ann Meeting, 1983.
7. Ereshefsky L, Saklad SR, Jann MW, Richards A, and Davis CM: Pharmacokinetics of
Fluphenazine (FPZ) by High Performance Thin Layer Chromatography. Proc Amer Psych Assoc
Annual Meeting, 1983.
8. Jann MW, Ereshefsky L, Saklad SR, Richards A, and Davis CM: Haloperidol and Reduced
Haloperidol Plasma Levels in Schizophrenic Patients. Drug Intelligence Clinical Pharmacy
1984; 18:507.
9. Saklad SR, Ereshefsky L, Jann MW, Richards A, and Munoz R: Lithium Clearance Decreases
with Increasing Lithium Levels. Drug Intelligence Clinical Pharmacy 1984; 17:507-508.
10. Curtis JL, Jann MW, Smith D, Ereshefsky L, Saklad SR: Use of Carbamazepine in Children and
Adolescents or Aggressive Behavior, 19th Annual Midyear Clinical Meeting by American
Society of Hospital Pharmacists.
11. Young D, Ereshefsky L, Saklad SR, Jann MW, and Garcia NR: Pharmacokinetics of
Fluphenazine by Computer Simulations. Presented at the 19th Annual Midyear Clinical Meeting
by American Society of Hospital Pharmacists.
22
12. Jann MW, Ludden TM, Ereshefsky L, Saklad SR, and Richards AL: Preliminary Analysis of
Haloperidol Population Kinetics in Schizophrenics. Clinical Pharmacology and Therapeutics
1985;37:203.
13. Jann MW, Saklad SR, Ereshefsky L, Davis CM, Richards AL, and Burch NR: Effects of
Smoking on Haloperidol and Reduced Plasma Levels. World Congress on Biological Psychiatry,
Philadelphia, Pennsylvania, September 9-15, 1985. International Journal of Neuroscience.
14. Ereshefsky L, Birkhimer LY, Young D, Saklad SR, and Jann MW: A Pharmacokinetic Model for
Depot Neuroleptics. Proc 45th Int Cong Pharm Sci FIP 1985:160.
15. Saklad SR, Ereshefsky L, Jann MW, Ward ME, Richards AL, Birkhimer LJ: Usefulness of
Injectable and Oral Lorazepam in Psychotic and Developmentally Disabled Patients. Proc Amer
Psych Assoc Journal Meeting, 1985.
16. Jann MW, Fidone G, Hernandez J, Collerain I, Bonadero P, and Aavis CM: Serum Haloperidol
Concentrations in the Treatment of Aggressive Retardates: A Preliminary Report. Proc ASHP
Midyear Clinical Meeting, December 1986.
17. Birkhimer L, Ereshefsky L, Saklad SR, Davis CM, and Jann MW: Thiothixene Pharmacokinetic
Interactions: A Preliminary Study of Enzyme Inducers and Inhibitors. Proc ASHP Midyear
Clinical Meeting, December 1986.
18. Jann MW, Fidone GS: Increased Valproic Acid Serum Concentrations Upon Carbamazepine
Cessation. Clinical Pharmacol Ther 1988; 43(2).178.
19. Ereshefsky L, Watanabe MD, Tran-Johnson TK, Jann MW, Saklad SR, Richards AL:
Determinants of doxepin oral clearance: The effects of demographic variables and drug
interactions. Pharmacotherapy, 1988; 8:114.
20. Jann MW, Lam YWF, Chang NH: Reversible metabolism of haloperidol and reduced haloperidol
in Chinese schizophrenics. Pharmacotherapy, 1989; 9:196.
21. Chang WH, Lam YWF, Jann MW, et al: Reduced haloperidol pharmacokinetics. J Clin
Pharmacology, 1989; 29:841.
22. Ethnic comparison of haloperidol and reduced haloperidol plasma levels; Chinese vs. Non-
Chinese. Chang WH, Jann MW, Hwu HG, Chen TY, Yeh EK, Chien CP. Colloquium
International Neuropsychopharmacology (CINP), Kyoto, Japan, Sept. 1990. Clin
Neuropharmacol.
23. Jann MW, D’Souza MJ, Pollock SH. Cyclosporine/Buspirone Interaction. Eur J Pharmacol
1990; 183(6):2296-7.
24. Jann MW, Fidone GF, Hernandez JH: Clinical Implications of Increased Antipsychotic plasma
concentrations upon anticonvulsant cessation. Psychiatry Digest 1990; 6:28-29.
25. Grimsley SR, D’Mello A, Jann MW, Carter GC, D’Souza MJ: Fluoxetine-Carbamazepine
Interaction. Pharm Res 1990; 7:(9 Suppl.)S-277.
26. Jann MW, Archer D, Nuyen N, et al: Cyclosporine azaperone interaction. Pharm Res 1990; 7:(9
Suppl.)S-253.
23
27. Chang WH, Jann MW, Lin SK, et al: Ethnic comparison of haloperidol and reduced haloperidol
plasma levels: Chinese vs. Non-Chinese. Clin Neurpharmacol 1990; 13(Suppl. 2): 850-1.
28. Chang WH, Jann MW, Lam YWF, et al: Comparative analysis of haloperidol plasma levels in
different ethnic populations. Biol Psychiatry, 1991: 29:62A.
29. Crabtree BL, Jann MW, Pitts WM: Alpha-one acid glycoprotein levels in schizophrenics. Biol
Psychiatry, 1991; 29:70A.
30. Woo J, Jann MW, Grimsley SR, Oliver J and Oettinger C. Plasma alpha-one acid glycoprotein
and albumin levels in different ethnic groups. J Clin Pharmacol, 1991;31:863.
31. Jann MW, Miller SW, Miyahara R, et al: A controlled clinical trial of nimodipine in the
treatment of primary degenerative dementia. Pharmacotherapy 1992; 12:507.
32. Jann MW, Miyahara R, Miller SW, et al: Long-term effects of nimodipine in patients with
primary degenerative dementia. Pharmacotherapy 1993; 13:291-292.
33. Jann MW, Chang SC, Lin SK, et al: Pharmacodynamic and pharmacokinetics of haloperidol after
intramuscular injection. Pharmacotherapy 1993; 15:291.
34. Jann MW, Chang WH, Chien RP: Reversible metabolism of clozapine and clozapine N-oxide.
American College of Clinical Neuropsychopharmacology, 1993; pp.203.
35. Chang WH, Juang DJ, Lane HY, Chien CP, Lam YWF, Jann MW: Reversible metabolism of
haloperidol in guinea pigs. Neuropsychopharmacol 1994; 10:148 S.
36. Huang HF, Jann MW, Chang WH, Tseng YT, Chien CP: Ketone reductase activity in haloperidol
treated schizophrenic patients. Neuropsychopharmacol 1994; 10:199 S.
37. Chien CP, Lin SK, Jann MW, Chang WH: Comparison of clozapine and desmethylaozaine
plasma level in Chinese vs. Non-Chinese schizophrenic patients. Neuropsychopharmacol, 1994;
10:248 S.
38. Lin SK, Wei FL, Lin HC, Chung MC, Jann MW, Chang WH: Plasma clozapine levels and
clinical response in refractory schizophrenics. Neuropsychopharmacol, 1994; 10:265 S.
39. Erikson SM, Carson SW, Grimsley SR, Carter JG, Kumer A: Effects of sertraline on steady-state
concentrations of imipramine and its metabolites. Pharmacotherapy, 1994; 14:368.
40. Jann MW, Carson SW, Grimsley SR, Erikson SM, Kuman A, Carter JG: Effect of Sertraline
upon imipramine pharmacodynamics, Clin Pharmacol Ther, 1995; 57:207.
41. Augustin B, Cold JA, Chow MA, Nelson E, Jann MW: Comparison of haloperidol and
risperidone on the positive and negative symptoms of schizophrenia. J Clin Pharmacol, 1995;
35:937.
42. Jann MW, Chang WH, Lin SK, et al.: Reversible metabolism of clozapine and clozapine N-
oxide in schizophrenic patients. CINP, 1996.
24
43. Augustin BG, Jann MW, Carter JG: Alpha-one acid glycoprotein and haloperidol plasma
concentrations in schizophrenics. CINP, 1996.
44. Augustin BG, Thurston A, Thomas G, Hui J, Jann MW: In-vitro metabolism of clozapine in
human hepatic microsomes. Clin Pharmacol Ther, 1997; 61:179.
45. Augustin BG, et al.: Encore presentation. Pharmacotherapy, 1997; 17:196.
46. ZumBrunnen TZ, Augustin BG, Cold JA, Awad EA, Jann MW: Red blood cell lithium
determinations from frozen samples. Pharmacotherapy, 1997; 17:192.
47. VanDenBerg CM, ZumBrunnen TZ, Cold JA, Jann MW: Utilization of saliva lithium levels:
detection of potential drug-drug interaction with NSAIDs. Pharmacotherapy, 1997; 17:1099.
48. Cold JA, Simpson MA, ZumBrunnen TZ, Grimsley SR, Augustin BG, Jann MW: Risperidone
and 9-OH metabolite plasma concentrations and prolactin and clinical responses in
schizophrenics. Pharmacotherapy, 1997; 17:1100.
49. Kazmi YR, ZumBrunnen TZ, Augustin BG, Tenjarla SN, Jann MW: Effects of ondansetron upon
neuroendocrine regulation of prolactin. Pharmacotherapy, 1997; 17:1110.
50. ZumBrunnen TZ, Jann MW, Tenjarla SN, et al.: Bioavailability of ondansetron 8 mg oral tablets
versus two extemporaneous 16 mg suppository formulations. Pharmacotherapy, 1997; 17:1111.
51. Chang WH, Lane HY, Liu HC, Chen CH, Chiu CC, Jann MW. Effect of fluvoxamine on
clozapine kinetics. Biol Psychiatry, 1998; 43:109S.
52. Lane HY, Chang WH, Lin SK, Jann MW. Effects of gender and age on plasma clozapine and
metabolite levels. Biol Psychiatry, 1998; 43:110S.
53. Jann MW and Cyrus PA. Once daily metrifonate dosing regimen without loading dose is
favorable to a loading dose regimen in Alzheimer’s Disease patients based upon a randomized
placebo-controlled trial. Pharmacotherapy, 1998; 18:1145.
54. Kazmi YR, Chang WH, Augustin BG, ZumBrunnen T, Lane HY, Liu HC, Chen CC, Chin CC,
Jann MW. Effects of fluvoxamine on clozapine metabolism: in vitro and in vivo findings.
Pharmacotherapy, 1998; 18:1161.
55. Grimsley SR, VanDenBerg C, Spratlin V, Jann MW. Clinical characteristics and health care
utilization in patients with panic disorder. Pharmacotherapy, 1998; 18:1162.
56. VanDenBerg CM, Grimsley SR, Spratlin V, Jann MW. Pharmacotherapeutic interventions in
patients with panic disorder. Pharmacotherapy, 1998; 18:1162.
57. Desai HD, Marshall L, Jann MW, Spartlin V. Impact of donepezil upon Alzheimer’s patients
discontinued from metrifonate. J Clin Pharmacology 2000; 40: 1048.
58. Penzak SR, Jann MW, Cold JA, Hon YY, Desai HD, Gurely BJ. Seville orange juice, synephrine
content and effect on blood pressure in healthy subjects. J Clin Pharmacology 2000; 40: 1055.
25
59. Jann MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ, Flockhart
DA. Relationship between fluvoxamine pharmacokinetics and CYP2C19 phenotype and
genotype. Pharmacotherapy 2001; 21: 1288.
60. Hon YY, Penzak SR, Shirley KL, Jann MW. Genetic polymorphism in the 5’flanking region of
CYP1A2 gene in Caucasians. Pharmacotherapy 2001; 21: 1286.
61. Hon YY Jann MW. Plasma and whole blood histamine concentrations in healthy subjects with
different histamine N-methyltransferase genotypes. Pharmacotherapy 2003; 23: 1357-1358.
62. Abifadel D, Jann MW, Matesic D. Effect of thioridazine on the major cardiac gap junction
subtype. SEPS, Atlanta, GA. Sept. 20, 2003.
63. Hon YY, Jusko WJ, Spratlin VE, Jann MW. Altered methylprednisolone pharmacodynamics in
healthy subjects with N-histamine methyltransferase (HNMT) C31T genetic polymorphism.
AAPS Annual Meeting, Baltimore, MD., Nov. 8-11, 2004.
64. Tsai GE, Lane HY, VanDenBerg CM, Liu YC, Tsai P, Jann MW. Disposition of D-serine in
healthy adults. College of Psychiatric and Neurologic Pharmacists, April 10-14, 2008. .
65. Foster KL, Jann MW. Introductory Pharmacy Practice Experience – Community Practice. AACP
Annual Meeting, Orlando, FL. July 16-19, 2008.
66. Broussard CS, Reefhuis, Friedman J, Rasmussen SA, Jann MW, Honein MA and National Birth
Defects Prevention Study. Maternal Therapeutic Use of Opioid Analgesics and Risk of Adverse
Fetal Health Outcomes., Int. Pharmacoepidemiology, July 2, 2008.
67. Broussard CS, Reefhuis, Friedman J, Rasmussen SA, Jann MW, Honein MA and National Birth
Defects Prevention Study. Opioid analgesic Treatment During Pregnancy and Adverse Fetal
Outcomes. Maternal Chil Epidmeiology Sept. 7-12, 2008.
68. Broussard CS, Rasmussen SA, Reefhuis, Friedman J, Jann MW, Honein MA and National Birth
Defects Prevention Study. Maternal opioid analgesic treatment and risk for major birth defects.
14th Maternal and Child Health Epdiemiology, Dec. 10-12, 2008.
69. Chaturvedula A, Metzger N, Fossler M, Jann MW. Development of population pharmacokinetic
model of vancomycin using single trough collected during routine therapeutic drug monitoring.
Clin Pharmacol Ther 2012; 91: S120.
70. Momary KM, Jann MW, Spratlin V, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg
CM. Lack of effect of ABCB1 genotype on the drug-drug interactions between indinavir and
venlafaxine extended-release or desvenlafaxine extended-release. Clin Pharmacol Ther 2012; 91:
S120-S121.
71. Jann MW, Penzak SR, White A, Tatachar. An elective course in LGBT Health and Practice.
AJPE 2018; 82 (5): 493. AACP Annual Meeting, Boston, MA., July 2018.
Other:
1. Jann MW: Benzodiazepines. Drug Information Bulletin, Cedars-Sinai Medical Center, pp. 1-6,
March 1981.
26
2. Jann MW, Crawford GA, Eacott R, et al: Final Report: Task Force on the Development of
Uniform Operating Procedures for Departmental Pharmacies. Presented to the Commissioner of
the Texas Department of Mental Health and Mental Retardation. 1982, pp. 1-288.
3. Jann MW, Saklad SR, and Bitar AH: Respiratory Dyskinesia. Author’s Reply. Psychosomatics
1983; 24:165.
4. Jann MW, Saklad SR, and Ereshefsky L: Carbamazepine Treatment of Psychiatric Inpatients
with Affective Symptoms. Drug Intelligence Clinical Pharmacy, Lt Editor, 1984; 18:81.
5. Ereshefsky L, Saklad SR, Davis CM, Jann MW, Richards AL, and Burch NR: Clinical
Implications of Fluphenazine Pharmacokinetics. Scientific Brochure 1984; 1-23.
6. Saklad SR, Ereshefsky L, Jann MW, Ward ME, Richards AL, Birkhimer LJ: Usefulness of
Injectable and Oral Lorazepam in Psychotic and Developmentally Disabled Patients. Scientific
Brochure, 1985; 1-23.
7. Grothe DL, Ereshefsky L, Jann MW, and Fidone G: Clinical Drug Interactions Between
Neuroleptics and Opioids. Drug Intelligence and Clinical Pharmacy 1986; 21:47(Ltr.).
8. Jann MW, Bean J, Perez I, and Fidone G: Interaction of Dietary Pudding with Phenytoin.
Pediatrics 1986; 78:952-953.
9. Fidone GS, Jann MW, Rosenthal S: Transitional Polytherapy, Liver Enzymes and Valproic Acid
Hepatotoxicity. Neurology 1987; 37:1692-3.
10. Jann MW, Chang WH, Lin SK: Reply. J of Clinical Psychopharmacology 1992; 12:135-136.
11. Jann MW: Non-physician Prescribing. J Clinical Psychiatry 1994; 55:414.
12. Jann MW: New uses for serotonergic uptake inhibitor antidepressants. Glaxo-Wellcome
Newsletter 1998.
13. Jann MW: Cholinesterase inhibitors for the treatment of Alzheimer’s Disease. Glaxo-Wellcome
Newsletter 1998.
14. Augustin BG, Jann MW: Generalized Anxiety Disorder: Case Study. Pharmacotherapy 1997; 1st
edition: 271-275.
15. Lane HY, Su KP, Chang WH, Jann MW. Elevated plasma clozapine concentrations after
phenobarbital discontinuation. Journal of Clinical Psychiatry, 1998; 59:131.
16. Penzak SR, Grimsley SR, Jann MW. Significant interaction with new antiretrovirals and
psychotropic drugs. Ann Pharmacother 1999; 33: 1372-3.
17. VanDenBerg CM, Jann MW: Generalized Anxiety Disorder: Case Study. Pharmacotherapy
2000; 4th edition 170-174.
18. Clinical Case Studies #2 - Jann MW. Impact of pharmacologic treatment of Alzheimer's Disease
on cognition, behavior, and activities of daily living. The Pharmacist on the Alzheimer's Disease
Treatment Team. CE Program, 2001.
27
19. Clinical Case Studies #3 - Shirley KL, Jann MW. Optimizing outcomes: role of the pharmacist.
The Pharmacist on the Alzheimer's Disease Treatment Team. CE Program, 2001.
20. Jann MW, Chang WH, Lane HY. Differences in haloperidol epidemiologic pharmacokinetic
studies. J Clin Psychopharmacology, 2001; 21: 628-630..
21. Jann MW: Generalized Anxiety Disorder: Case Study. Pharmacotherapy 2002; 5th edition , 202-
204.
22. Lu ML, Lane HY, Jann MW, Chang WH. Dosing strategies of clozapine-fluvoxamine
cotreatment. J Clin Psychopharmacol 2002; 22: 626-628.
23. Jann MW. Galantamine extended-release. CNS Drugs 2006; 20: 682-683.
Research Projects as Principle or Co-Principle Investigator:
1. “Prophylactic Effects of Lithium on the Switch Process in Bipolar Depressed Patients Treated
with Tricyclic Antidepressants,” University of Tennessee $2,000, 1980.
2. “A Comparative Evaluation Between Chlordiazepoxide-Amitriptyline and Doxepin,” Project
Coordinator residency research project at The University of Tennessee funded by the Pfizer
Company for $22,000, Phase IV, 1980.
3. “Effects on Influenza Vaccination on Serum Anticonvulsant Concentrations,” Funded by Texas
Department of Mental Health and Mental Retardation $1,500, 1985.
4. “Effects of Hemolysis on Serum Carbamazepine Concentrations,” TDMHMR $5,000, 1986.
5. “Use of Butorphanol as a Presedative Agent in the Mentally Retarded,” Funded by Bristol-Myers
$3,000, 1986.
6. “Multi-Center/Double-Blind Comparison of BMY 13859. Thioridazine, Haloperidol and
Placebo in Schizophrenic Patients.” Funded by Bristol-Myers, $60,000, Phase II, 1986-87.
7. “Double-Blind Comparison of Tiospirone, Haloperidol and Placebo in Schizophrenic Patients.”
Funded by Bristol-Myers, $261,000, Phase II, 1987-89.
8. “Open Multi-Center Evaluation of the Efficacy and Safety of Orally Administered GR-C507/75
in Hospitalized Patients with Schizophrenia,” Funded by Glaxo, Inc., $20,000, Phase II, 1987-88.
9. “Clinical Efficacy Trial of Lamotrigine - A New Anticonvulsant,” Funding status-pending by
Burroughs-Wellcome, $130,000, Phase III, 1988.
10. “Interagency Contract,” San Antonio State Hospital, 1988-1989, $25,640.
11. “A Phase III study of the efficacy and safety of nimodipine in patients with primary degenerative
dementia,” Funded by Miles Laboratory, $293,172.00, 1989-1991.
12. “Cyclosporine/Buspirone interaction,” Funded by Bristol/Myers, $1,000, 1989.
28
13. Comparison of the interconversion process of haloperidol and reduced haloperidol. Jann MW
and D’Souza MJ. Submitted to the American Health Assistance Foundation. 1990-1992,
$83,601.00, approved - not funded.
14. “Interconversion of haloperidol and reduced haloperidol. NIA/NIH RFA-AG-89-05,” Total
Costs $158,750.00, 1990-1992, approved - not funded priority score 317.
15. “Compassionate Use of Nimodipine in PDD Patients,” Funded by Miles Labs, $2,500, 1990-
1991.
16. “Acute and Chronic Effects of Nicorette on the Kinetics/Dynamics of Imipramine,” Submitted to
the Smokeless Tobacco Research Council, 1991, $47,100, approved - not funded.
17. “Disposition of haloperidol and its reduced metabolite in agitated ICU patients,” Submitted to
the American Col of Clinical Pharmacy, $10,000, 1991 not funded, mean score 87.5/100.
18. “A prospective multicenter open-label study of the safety of abecarnil in outpatients with
generalized anxiety disorder,” Funded by Sandoz, $87,150, 1992-1993.
19. “Reversible metabolism of haloperidol. NIH AREA.” Total costs. $74,255, 1992-94, approved -
not funded, priority score 210.
20. “Pharmacodynamics and kinetic interaction study between cyclosporine/antidepressants,”
American Heart Association - Georgia Affiliate. 1992-93, $27,430, not funded.
21. “A phase III study of the efficacy and safety of nimodipine in the treatment of primary
degenerative dementia (P.D.) of the Alzheimer’s Type,” Funded by Miles Labs. $383,000, 1992-
1995.
22. “The role of monoamine in the pathogenesis of mental disorders and the mode of action of
psychotropic drugs,” National Science Council Scholar’s Program, Republic of China, $7,600/yr,
1992-1995.
23. “Use of Paroxetine in depressed patients,” Funded by Smith, Kline, Beecham, $10,000, 1993-
1994.
24. “Sertraline - imipramine interaction study,” Funded by Pfizer, $2,000, 1993.
25. “A multicenter, double-blind, placebo controlled, parallel group, dose-ranging study to evaluate
the efficacy, safety and tolerability of zotepine 75, 150, 300 mg daily doses in the treatment of
schizophrenia,” Funded by Boots Pharmaceutical, $140,000, 1993-1995.
26. “A multicenter, double-blind, placebo controlled study of velnacrine in the treatment of
Alzheimer’s Disease - NINCDS/ARDA” Funded by Hoechst $144,000, 1993-1994.
27. “A multicenter, double-blind, placebo-controlled study of metrifonate D3-029 in the treatment of
P.D. of the Alzheimer’s type,” Funded by Miles. $239,000, 1994-1995.
28. “An open trial of metrifonate X-93-029 in the treatment of P.D. of the Alzheimer’s type,” Funded
by Miles, $147,725, 1994-1996.
29
29. “A multicenter, double-blind, placebo controlled study of AF102B in the treatment of P.D. of the
Alzheimer’s type,” Funded by Forest Labs, 1995-1996, $250,000.
30. “Risperidone QD vs. BID Dosing in Schizophrenia,” Funded by Janssen, $104,000, 1995-1996.
31. “Clinical Research Fellowship Program” Solvay Pharmaceuticals, $80,000, 1996-1998; renewed
1999-2001, $80,000.
32. “In-vitro models of cytochrome P450 isozymes to predict drug interactions,” Solvay
Pharmaceuticals $12,000, 1995-1996; renewed 1996-1997, $13,000; renewed 1997-1998,
$13,000; renewed 1998-1999, $13,000; renewed $35,000, 1999-2000.
33. “A multicenter, double-blind placebo control trial of metrifonate D95 (Phase III) in the treatment
of Alzheimer’s Disease,” Funded by Bayer, $294,576, 1995-1996.
34. “A continuation study of the open trial of metrifonate Y-93 in the treatment of Alzheimer’s
Disease,” Funded by Bayer, $67,500, 1996-1997.
35. “Pharmacokinetic and pharmacodynamic interaction study between nefazodone and grapefruit
juice,” Funded by Bristol-Myers Squibb, $5,000, 1996.
36. “An open trial of metrifonate in the treatment of patients with probable Alzheimer’s Disease -
extension of D95,” Funded by Bayer, $184,300, 1996-1998.
37. “Disposition of fluvoxamine in poor versus extensive metabolizers of P450 2C19,” Funded by
Solvay Pharmaceuticals, $6,000, 1996.
38. “A multi-center, double-blind fixed dose study of metrifonate D-96-010 in patients with probable
Alzheimer’s Disease,” Funded by Bayer, $153,000, 1996-97.
39. “A multi-center, double-blind placebo control trial of SDZ ENA 713 in the treatment of
Alzheimer’s Disease,” Funded by Sandoz, $88,130, 1996.
40. “An open label study of SDZ ENA 713 in the treatment of Alzheimer’s Disease,”
Funded by Sandoz, $86,000, 1996-97.
41. “Bioavailability study of two Zofran 16 mg Suppository Formulations v.s. 8 mg Oral
Tablet,” Funded by Glaxo/Wellcome, $60,315, 1996-97.
42. “A loading dose versus non-loading dose of Metrifonate (D96-038) in the treatment of patients
with probable Alzheimer’s Disease,” Funded by Bayer, $260,000, 1996-1997.
43. “An open label trial of Metrifonate (X96-010) in the treatment of patients with probable
Alzheimer’s Disease,” Funded by Bayer, $316,000, 1997-1998.
44. “Long-term treatment with Metrifonate (U96-001) in patients with probable Alzheimer’s
Disease,” Funded by Bayer, $165,000, 1997-1999.
45. “Evaluation of Exelon (ENA 713) in patients with probable Alzheimer’s Disease in the
community,” Funded by Sandoz, $207,000, 1997-1998.
30
46. “Double-blind placebo controlled trial of Lazabemide in the treatment of patients with probable
Alzheimer’s Disease,” Funded by Hoffman LaRoche, $250,000, 1997-1998.
47. “Pharmacokinetic studies of new xenobiotics in rats,” Funded by Solvay, $43,000, 1998-1999;
$70,000 1999-2000.
48. “A double-blind placebo-controlled study of donepezil (Aricept®) patients with vascular
dementia,” Funded by Pfizer, $200,800, 1997-1998.
49. “A double-blind placebo-controlled study of aripiprazole in the treatment of psychosis, with
risperidone as active control,” Funded by Otsuka Pharmaceuticals, $473,000, 1997-1998.
50. “An open-label follow-up study of the long-term safety of aripiprazole in patients with
psychosis,” Funded by Otsuka Pharmaceuticals, $160,000, 1997-1999.
51. “Bioavailability of ondansetron: IV versus oral versus suppository formulation,” Funded by
Glaxo-Wellcome, $40,300, 1998.
52. “A double-blind placebo-controlled study to evaluate metrifonate in vascular dementia,” Funded
by Bayer, $76,000, 1998-1999, study was withdrawn in 1999.
53. “Economic and quality of life evaluation of Exelon® in patients with probable Alzheimer’s
disease.” Funded by Novartis, $39,000, 1998-1999. Co-PI with Dr. T. Grapes.
54. “Switch study from antipsychotics to aripiprazole.” Funded by Otsuka Pharmaceuticals,
$140,000, 1999-2000.
55. “Bioavailability of sumatripin oral 25 mg tablet vs. 25 mg extemporaneous suppository.” Funded
by Glaxo Wellcome, $50,900, 1999-2000.
56. “Pharmacokinetic and pharmacodynamic interaction study between lithium and COX-2
inhibitors,: not funded by Solvay Pharmaceuticals, $48,000.
57. “In-vitro and in-vivo correlations of interactions with protease inhibitors,” submitted to the FDA
under RFA FDA CDER 2000, $1,121,278 for 2000-03. Priority score 220, approved, not
funded.
58. “A phase III double-blind placebo control study of aripiprazole in schizophrenic patients.”
Funded by Bristol Myer’s Squibb, $354,000, 2000-2001.
59. “A phase III study with sustained release Adderall in children with ADHD.” Funded by Shire
Labs, $182,000, 2000-2001.
60. “A phase III double-blind placebo control study of aripiprazole in bipolar patients.” Funded by
Bristol Myer’s Squibb, $319,000, 2000-2001.
61. “CYP 2D6 and 3A4 genotypes in elderly patients treated with antipsychotics.” Submitted
NIA/NIH, $306,900 for 2001-06, priority score 205, approved, not funded.
62. "A double-blind phase III clinical trial of pregabalin for postherpetic neuralgia." Funded by
Pfizer, $305,000 for 2000-2001.
31
63. “A double-blind placebo controlled trial of galantamine in the treatment of patients with
Dementia with Lewy Body (DLB).” Funded by Janssen $100,000 for 2001-2002.
64. “An open label phase III study of pregabalin for chronic pain syndromes.” Funded by Pfizer,
$330,000 for 2001-03.
65. “Olanzapine and lamotrigine interaction study in healthy volunteers.” Funded by Lilly, $59,500
for 2002-03.
66. “A randomized open-label multicenter 6 arm study evaluating the effect of oral iloperidone at
three doses versus other antispychotics on QTc interval duration in otherwise healthy patients
diagnosed with schizophrenia or schizoaffective disorder.” Funded by Novartis, $899,387 for
2001-02.
67. “A multicenter double-blind randomized placebo controlled parallel group evaluation of
lamotrigine adjunctive therapy in subjects with primary generalized tonic-clonic seizures.”
Funded by Glaxo Wellcome Research, $60,000 for 2001-03.
68. “New drug formulation of fenofibrate in healthy volunteers.” Funded by Lipocine, $42,000 for
2001-02. Co-PI with Dr. Christine Hon.
69. “Comparison of fenofibrate formulations #1 and #2 versus Tricor in healthy volunteers.” Funded
by Lipocine, $43,800 for 2002-03. Co-PI with Dr. Christine Hon.
70. “New drug formularion of zolipdem in healthy volunteers.” Funded by Lipocine, $27,500 for
2002-03. Co-PI with Dr. Christine Hon.
71. “Single dose in vivo study of lipocine LPCN 1013 formulation versus a commercial reference.”
Funded by Lipocine $81,500, 2002-03. Co-PI with Dr. Christine Hon.
72. “Single dose pharmacokinetic study of Lipocine cilostazol capsule 01, Lipocine capsule 02
versus Pletal cilostazol tablet.” Funded by Lipocine $43,920 for 2003.
73. “A multicenter double blind randomized placebo controlled study of reboxetine in patients with
post-herpetic neuralgia.” Funded by Pfizer $60,000 for 2004-05.
74. “Single dose pharmacokinetic study of of Lipocine fenofibrate –01 and 02 capsules and Tricor
tablets. Funded by Lipocine $42,000 for 2004.
75. “Double-blind placebo controlled trial of ONO 2506 in treatment of Alzheimer’s Disease.”
Funded by ONO Pharmaceuticals $212,360 2004-2006.
76. “Single dose pharmacokinetic study of Lipocine 01- and 02 versus Pletal in healthy volunteers.”
Funded by Lipocine $83,000 for 2004.
77. “Single dose pharmacokinetics of fenofibrate of Lipocine capsules 01-03 versus Tricor tablets.”
Funded by Lipocine $84,288 for 2005-06.
78. “An open label phase I study on a new atypical antipsychotic to explore in vitro/in vivo
correlation of an investigational drug long-acting formulation and two other formulations
protocol R092670 in schizophrenic patients.” Funded by Johnson/Johnson $250,000 for 2005-
2006.
32
79. “An evaluation of transdermal acyclovir pharmacokinetics by microdialysis enhanced by
ultrasound versus iontophoresis.” Funded by GSK $44,500 for 2005-2006.
80. “CE-MS of Biological Substances Using Chiral Polymers.” Co-PI (5% effort) with Shahab
Shamsi (Georgia State University). $1,178,855 FY 2008-2012, NIGMS, NIH #GM-0622314;
priority score 138, percentile 7.2. Funded.
81. “Drug utilization of antipsychotic medications in southwest rural Georgia.” Funded by Janssen
Foundation $120,400 for 2010-2011.
82. “A pharmacokinetic drug-drug interaction study with venlafaxine XR/indinavir and
desvenlafaxine /indinavir in healthy volunteers.” Funded by Wyeth/Pfizer $127,416 for 2010-
2011.
83. “Genetic polymorphism in P-glycoprotein with venlafaxine XR and desvenlafaxine XR
disposition in healthy volunteers.” Funded by Pfizer $7,500 2010-11 (Co-PI with Dr. Kathryn
Momary).
84. “A rapid loading dose scheme for paliperidone palmitate in the treatment of patients with
schizophrenia.” Funded by Janssen Foundation $300,000 for 2011-2012, project approved but
not conducted.
85. “Academic Detailing.” Co-PI (5% effort) with Barry Patel (Total Therapeutic Management).
Agency for Healthcare Research and Quality (AHRQ) 10-10011funded for $11.6 million 2011-
2013.
86. “Clinical pharmacy in ambulatory care clinic” – CMS 1115 Waiver project $202,000/year 2014-
2016. Dr. Bullock assumed PI role 2015. Renewal submitted for 2017-2020 under Dr. Katura
Bullock as PI.
87. “Determination of Glomerular Filtration Rate (GFR) in Transgender Persons.” NIH RFP PA-18-
718, Research on the Health of Transgender and Gender Nonconforming Populations. PI,
requested $275,000 direct costs 2019-2021, under review NIH/NIDDK.
Research Projects as Co-Investigator:
1. “A Multicenter Study to Evaluate the Pharmacokinetic and Clinical Interactions Between
Alprazolam and Imipramine.” Funded by the Upjohn Company, $24,000, Phase IV, 1984.
2. “Antidepressant Effects of Indalpine.” Funded by Rorer Pharmaceutical Company, $80,600,
Phase III, 1984.
3. “Comparative Bioavailability of Oral Fluphenazine Products.” Funded by E.R. Squibb and Sons,
$10,000, Phase IV, 1984.
4. “Lorazepam’s Use in Psychotic Patients and Developmentally Disabled Clients.” Co-
investigator, Funded by Wyeth $7,000, 1985.
5. “Double-Blind Comparative Evaluation of Oral Clozaril Versus Chlorpromazine Plus Cogentin
in Treatment Resistant Schizophrenic Patients Who Failed on Haloperidol Plus Cogentin.”
Funded by Sandoz, $160,000, Phase III, 1986.
33
6. “RBC and Plasma Concentrations of Haloperidol and Reduced Haloperidol Versus Response in
Acute Schizophrenics.” Phase IV, $12,000, 1985.
7. “A Study to Compare the Single Versus Multiple Dose Pharmacokinetics of Clozapine in
Psychiatric Patients.” Funded by Sandoz, Inc., $42,000, Phase III, 1987.
8. “Pharmacokinetic/Pharmacodynamic Interaction Between Alprazolam and Lithium.” Funded by
the Upjohn Company, $27,000, Phase IV, 1987.
9. “Bioavailability of Old Versus New Chlorprothixene Tablets in Schizophrenics.” Funded by the
Roche Company, $150,00, Phase I, 1987-88.
10. “Cost of Diagnosing Panic Disorders.” Funded by Upjohn $3,059, 1989.
11.“Psychobiology of Ethnicity.” Research Center, UCLA/Harbour General PA-92-122, NIMH in
1996-2001 (Fellowship Support $55,000/yr for 5 years).
12.”Gadolinium-CP027 pre-clinical pharmacology and toxicology in mice, rats, and dogs.” Dr.
Daniel Parrott UTSW (PI) Department of Radiology CPRIT grant ($20,000 0.1 FTE faculty support)
2018-2019. Subsequent CPRIT Grant Application in preparation (my role 0.2 FTE) for the phase “0”
and phase I studies planned for 2020-2022.